Veru Inc. (NASDAQ:VERU) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, ... which is Wegovy, ...

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that ...

In January 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study, which is a multicenter, double-blind, placebo-controlled, randomized, dose-finding ...

Veru currently has sufficient drug substance to supply the proposed Phase 2 clinical study. Second Quarter Financial Summary: Fiscal 2025 vs Fiscal 2024 Research and development expenses increased ...

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...

CEO Mitchell Steiner emphasized Veru’s focus on its obesity program, highlighting the positive Phase 2b clinical trial results for enobosarm. This drug, when combined with semaglutide ...

Study compares effectiveness of popular weight loss drugs 02:38. Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug. Latest U.S.

According to the Associated Press, trial participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 ...

Hims & Hers Health Inc.’s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...